Effects of the 5α-reductase inhibitor finasteride on serum levels of gonadal, adrenal, and hypophyseal hormones and its clinical significance: A prospective clinical study

Steroids

Volumn 63, Issue 4, 1998, Pages 208-213

  Uygur, Mehmet Cemil ^a,b   Arik, Ali Ihsan ^a   Altuǧ, Uǧur ^a   Erol, Demokan ^a  

^a ANKARA NUMUNE HOSPITAL   (Turkey)

^b NONE   (Turkey)

Author keywords

5 reductase inhibitor; Benign prostatic hyperplasia; Finasteride; Hormones; Sexual dysfunction

Indexed keywords

ALDOSTERONE; ANDROSTANOLONE; FINASTERIDE; FOLLITROPIN; HYDROCORTISONE; LUTEINIZING HORMONE; PRASTERONE; PROLACTIN; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE INHIBITOR; TESTOSTERONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; HORMONE BLOOD LEVEL; HUMAN; MALE; ORAL DRUG ADMINISTRATION; OUTCOMES RESEARCH; PHYSICAL EXAMINATION; PROSTATE; PROSTATE HYPERTROPHY; QUESTIONNAIRE; SEXUAL DYSFUNCTION; SEXUAL FUNCTION; SYMPTOMATOLOGY; URINARY TRACT OBSTRUCTION; URINE FLOW RATE;

ADULT; AGED; ALDOSTERONE; ANDROGENS; DEHYDROEPIANDROSTERONE; DIHYDROTESTOSTERONE; ENZYME INHIBITORS; FINASTERIDE; FOLLICLE STIMULATING HORMONE; GONADOTROPINS, PITUITARY; HUMANS; HYDROCORTISONE; LUTEINIZING HORMONE; MALE; MIDDLE AGED; PREGNENEDIONES; PROSPECTIVE STUDIES; PROSTATIC HYPERPLASIA; TESTOSTERONE; TESTOSTERONE 5-ALPHA-REDUCTASE;

EID: 0032055642     PISSN: 0039128X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-128X(98)00005-1     Document Type: Article

References (29)

1. 1. Lyyton B, Emery JM, Harvard BM (1968). The incidence of benign prostatic obstruction. J Urol 99:639-645.
2. 2. Guess HA (1992). Benign prostatic hyperplasia: antecedents and natural history. Epidemiol Rev 14:131-153.
3. 3. Berry SJ, Coffey DS, Walsh PC, Ewing LL (1984). The development of human benign prostatic hyperplasia with age. J Urol 141: 474-479.
4. 4. Andersen JT (1982). Prostatism, clinical, urodynamic and radiological aspects. Neurol Urodyn 1:241-293.
5. 5. Imperato-McGinley J, Guerrero L, Gautier T, Peterson RE (1974). Steroid 5α-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science (Washington, DC) 186:1213-1215.
6. 6. Brooks JR, Berman C, Primka RL, Reynolds GF, Rasmusson GH (1986). 5α-Reductase inhibitory and anti-androgenic activities of some 4-azasteroids in the rat. Steroids 47:1-19.
7. 7. Stoner E (1994). Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology 43:284-294.
8. 8. Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McConnell JD, Andriole GL, Geller J, Bracken BR, Tenover JS, Vaughan ED, Pappas F, Taylor A, Binkowitz B, Ng J, The Finasteride Study Group (1992). The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med 327:1185-1191.
9. 9. Boyle P, Gould AL, Roehrborn CG (1996). Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: Meta-analysis of randomized clinical trials. Urology 48:398-405.
10. 10. Nickel JC, Fradet Y, Boake RC, Pommerville PJ, Perreault JP, Afridi SK, Elhilali MM, The PROSPECT Study Group (1996). Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT Study) Can Med Assoc J 155:1251-1259.
11. 11. Wilton L, Pearce G, Edet E, Freemantle S, Stephens MDB, Mann RD (1996). The safety of finasteride used in benign prostatic hypertrophy: a non-interventional observational cohort study in 14,772 patients. Brit J Urol 78:379-384.
12. 12. Moore E, Bracken B, Bremmer W, Geller J, Imperato-McGinley J, McConnell J, Roy J, Tenover L, Vaughan D, Pappas F, Cook T, Gormley G, Stoner E (1995). Proscar: five year experience. Eur Urol 28:304-309.
13. 13. Vermeulen A, Giagulli VA, De Schepper P, Buntinx A (1991). Hormonal effects of a 5α-reductase inhibitor (finasteride) on hormonal levels in normal men and in patients with benign prostatic hyperplasia. Eur Urol 20 (Suppl 2):82-86.
14. 14. Cunningham GR, Hirtshkowitz M (1995). Inhibition of steroid 5α-reductase with finasteride: sleep-related erections, potency, and libido in healthy men J Clin Endocrinol Metab 80:1934-1940.
15. 15. O'Leary MP, Fowler FJ, Lenderking WR, Barber B, Sagnier PP, Guess HA, Barry MJ (1995). A brief male sexual function inventory for urology. Urology 46:697-706.
16. 16. Boyarsky S, Jones G, Paulson DF, Prout GR Jr (1976). A new look at bladder neck obstruction by the Food and Drug Administration regulators: guidelines for investigation of benign prostatic hypertrophy. Trans Am Assoc Genitourin Surg 68:29-32.
17. 17. Bolognese JA, Kozloff RC, Kunik SC, Grino PB, Patrick DL, Stoner E (1992). Validation of a symptoms questionnaire for benign prostatic hyperplasia. Prostate 21:247-254.
18. 18. McConnel JD (1990). Medical management of benign prostatic hyperplasia with androgen suppression. Prostate 3 (Suppl):49-59.
19. 19. Peters DH, Sorkin EM (1993). Finasteride: a review of its potential in the treatment of benign prostatic hyperplasia. Drugs 46:177-208.
20. 20. Ohtawa M, Morikawa H, Shimazaki J (1991). Pharmacokinetics and biochemical efficacy after single and multiple oral administration of N-(2-methyl-2-propyl)-3-oxo-4-aza-5α-androst-1-ene-17β-carboxamide, a new type of specific competitive inhibitor of testosterone 5α-reductase in volunteers. Eur J Drug Metab Pharm 16:51-68.
21. 21. Rittmaster RS, Stoner E, Thompson DL, Nance D, Lasseter KC (1989). Effect of MK-906, a specific 5α-reductase inhibitor, on serum androgens and androgen conjugates in normal men. J Androl 10:259-262.
22. 22. Raynaud JP, Authie D, Deschaseaux P, Périer A, Fiet J, Perrin P (1997). Influence of age and endocrin treatments (permixon® and finasteride) on sexual function in benign prostatic hyperplasia (BPH) patients. Brit J Urol 80 (Suppl 2):206, A 805.
23. 23. Schiavi RC, Rehman J (1995). Sexuality and aging. Urol Clin North Am 22:711-726.
24. 24. Calais Da Silva F, Marquis P, Deschaseaux P, Gineste JL, Cauquil J, Patrick DL (1997): Relative importance of sexuality and quality of life in patients with prostatic symptoms. Results of an international study. Eur Urol 31:272-280.
25. 25. Davidson JM, Camargo CA, Smith ER (1979). Effects of androgen on sexual behavior in hypogonadal men. J Clin Endocrinol Metab 48:955-958.
26. 26. Andersson S, Russel DW (1990). Structural and biochemical properties of cloned and expressed human and rat 5α-reductase. Proc Natl Acad Sci USA 87:3640-3644.
27. 27. Jenkins EP, Andersson S, Imperato-McGinley J, Wilson JD, Russel DW (1992). Genetic and pharmacological evidence for more than one human steroid 5α-reductase. J Clin Invest 89:293-300.
28. 28. Thigpen AE, Silver RI, Guileyardo JM, Casey ML, McConnel JD, Russel DW (1993). Tissue distribution and ontogeny of steroid 5α-reductase isozyme expression. J Clin Invest 92:903-910.
29. 29. Seyam RM, Huynh HT, Bégin LR, Rittmaster RS, Macramalla AN, Abdelbaky TM, Dion SB, Brock GB (1997). 5α-Reductase inhibition induces a biphasic regulatory response in transcription of neuronal and endothelial nitric oxide synthase: new insights into the role of androgenic control of erection. J Urol 157 (Suppl): A 1389.